Back to Awarded Treatment Trials
Awarded Trial: 01-122
Grant ID
01-122
Illness
Bipolar Disorder
Primary Drug/Intervention
Mexiletine
Primary Dosage
600-800 mg
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Schaffer
Sample Size
20
Duration of Study Period for Each Subject
3 weeks
Outcome Measurements
YMRS, CGI
Results
Ten patients with bipolar disorder received mexiletine or placebo adjunctively to other psychotropic medications for three weeks. Although the small sample size precluded accurate statistical comparisons, mexiletine treated patients appeared to have improved scores on the Young Mania Rating Scale (YMRS). There also appeared to be a greater number of "responders" (reduction of YMRS score by 50%) in the mexiletine group at week 1 and week 2.
Publication
Schaffer A, Levitt AJ. Double-blind, placebo-controlled pilot study of mexiletin for acute mania or hypomania (letter). J Clin Psychopharmacol 2005;25:507-508.
Link
http://www.ncbi.nlm.nih.gov/pubmed/16160638
PI Name
Ayal Schaffer
Degree
MD
Center
University of Toronto, Department of Psychiatry
Institution
Sunnybrook & Women's College Health Sciences Centre
Address
2075 Bayview Ave, Room FG 29
City or Town
Toronto
State or Province
Ontario
Zip or Postal Code
M4N 3M5
Country
Canada
Email Address
ayal.schaffer@sw.ca